| Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
| Genedrive Plc |
LSE:GDR |
London |
Ordinary Share |
GB00B1VKB244 |
ORD 1.5P |
| |
Price Change |
% Change |
Share Price |
Shares Traded |
Last Trade |
| |
9.50 |
48.72% |
29.00 |
3,630,709 |
16:35:04 |
| Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
|
27.00
|
30.00
|
30.00 |
19.50 |
19.50 |
| Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
|
Pharmaceuticals & Biotechnology
|
2.36
|
-4.52
|
-14.00
|
|
10
|
| Last Trade Time |
Trade Type |
Trade Size |
Trade Price |
Currency |
| 16:36:35 |
O |
50,000 |
29.50 |
GBX |
| Trade Time |
Trade Price |
Trade Size |
Trade Value |
Trade Type |
| 17:11:50 | 29.50 | 50,000 | 14,750.00 | O |
| 16:41:37 | 30.00 | 50,000 | 15,000.00 | O |
| 16:36:36 | 29.25 | 30,000 | 8,775.00 | O |
| 16:32:58 | 28.31 | 75,000 | 21,229.13 | O |
| 16:17:45 | 29.26 | 25,000 | 7,315.00 | O |
| Date | Subject |
|---|
30/3/2020
09:20 | Genedrive Daily Update: Genedrive Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 19.50p.
Genedrive Plc has a 4 week average price of 8.75p and a 12 week average price of 6.50p.
The 1 year high share price is 38.50p while the 1 year low share price is currently 6.50p.
There are currently 34,000,506 shares in issue and the average daily traded volume is 2,907,600 shares. The market capitalisation of Genedrive Plc is £9,860,146.74.
|
25/3/2020
08:48 | the ghost who walks: Yes it's amazing.Glad to be proved wrong, hoping that they now deliver and then raise at a much much higher share price.Note it's still below 20 which is bizarre.
|
17/10/2017
14:37 | walbrock82: Despite the rise in today’s share price, Genedrive’s results are poor. Revenue missed their £7m forecast and net losses widened to £6.4m, greater than their sales of £5.8m.
The problems facing this diagnostic business is two-fold:
-One R&D expenses account for 90% of group sales (normally you would expect 20%). Also, it grows larger as sales increase.
-Two staff costs represent half of sales.
Also, 40% of group sales is reliance on grant funding which is a volatile source of income. But, right now it is helping to mask internal sales weakness within the business.
Those who participate in last year placing at 80p is down by 55%.
For more Genedrive analysis and other analysis on companies’ results, click http://bit.ly/2hLViFb
|
Genedrive share price data is direct from the London Stock Exchange
PLUS1
Genedrive Shares Soar As It Says It Will Develop SARS-COV-2 Tests